Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.

Inclusion Criteria:

• Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
• Male or female aged 18-65 years (both inclusive)
• T2DM diagnosis

Exclusion Criteria:

• Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics
• Use of GLP-1 mimetics or DPP-IV inhibitors
• Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%